What’s New with the RSV Vaccine This Season?

Keyword focus: rsv vaccine news

Respiratory syncytial virus (RSV) causes seasonal outbreaks of cough, fever and breathing difficulties in infants, older adults and people with certain health conditions. Historically, we’ve relied on preventive measures like handwashing and avoiding close contact with sick individuals. This season, however, marks a turning point: new RSV vaccines are now available for adults, and maternal vaccination is an option to protect infants. Here’s the latest on RSV vaccine news, who should get vaccinated, safety data and practical next steps.

Recent RSV Vaccine Approvals

Two vaccines now hold FDA approval for RSV prevention in specific groups:

• Arexvy (GSK)
– Approved for adults aged 60 years and older (September 2023)
– Single-dose, recombinant subunit vaccine targeting the RSV F protein
– Designed to boost waning immunity in seniors

• Abrysvo (Pfizer)
– Approved for pregnant people to protect infants from birth through 6 months (August 2023)
– Single-dose, recombinant subunit vaccine given between 32 and 36 weeks’ gestation
– Also under review by ACIP for direct use in adults 60+

These approvals stem from large clinical trials demonstrating significant reductions in RSV-related lower respiratory tract illness.

Key Findings from Clinical Trials

Both vaccines showed strong efficacy and acceptable safety profiles:

• Arexvy trial in adults 60+ (over 25,000 participants):
– 82.6% reduction in RSV-related lower respiratory tract disease
– Benefits observed across age brackets (60–69, 70–79, 80+)

• Abrysvo maternal immunization study (over 7,300 participants):
– 82% reduction in severe RSV illness in infants during first 90 days
– 69% reduction through six months
– Comparable rates of pregnancy and neonatal adverse events vs. placebo

Side effects were generally mild to moderate. Common reactions included injection-site pain, fatigue and muscle aches. Serious adverse events were rare and occurred at similar rates in vaccine and placebo groups.

Updated Guidance and Recommendations

The Advisory Committee on Immunization Practices (ACIP) met in June 2024 to review the data. Their provisional recommendations include:

• Adults 60 years and older
– May receive a single dose of an FDA-approved RSV vaccine (Arexvy or Abrysvo, if approved)
– Shared decision-making: discuss individual risk factors (heart or lung disease, immunocompromise) with a healthcare provider

• Pregnant people
– One dose of Abrysvo between 32 and 36 weeks’ gestation
– Aims to transfer maternal antibodies across the placenta

• Infants under 6 months
– Protected indirectly by maternal immunization
– No direct vaccine licensed yet; monoclonal antibody (nirsevimab) is available for high-risk infants

These guidelines may be updated as more data emerge, especially on duration of protection and cost-effectiveness.

Who Should Consider RSV Vaccination?

Talk to your healthcare provider if you fall into any of these groups:

• Adults 60 years or older
• Pregnant people in the recommended gestational window
• People of any age with chronic heart or lung disease, diabetes, chronic kidney disease or immunocompromising conditions
• Caregivers and household contacts of infants under 6 months

Deciding on vaccination involves weighing personal health risks, local RSV activity and vaccine availability.

Safety and Side Effects at a Glance

Most side effects are short-lived and resolve without treatment. Typical reactions include:

• Injection-site pain or redness
• Fatigue or malaise
• Headache
• Muscle or joint aches
• Fever (usually low grade)

Severe allergic reactions (anaphylaxis) are very rare. Vaccination sites are equipped to manage immediate reactions. Report any concerning or persistent symptoms to your healthcare provider.

Insurance Coverage and Accessibility

• Medicare Part B covers RSV vaccination for eligible seniors under preventive services.
• Many private plans cover FDA-approved RSV vaccines under their immunization benefits.
• Some state health departments offer vaccines at low or no cost for uninsured or underinsured individuals.
• Check with your pharmacy, primary care office or local health department about availability.

What to Expect When You Get Vaccinated

1. Pre-Vaccination Discussion: Review your medical history and current medications.
2. Administration: Single injection in the upper arm.
3. Post-Vaccination Monitoring: Wait 15 minutes on site to watch for immediate reactions.
4. Symptom Tracking: Note any side effects, typically peaking within 48 hours.

Ongoing Research and Future Directions

• Broader Age Indications: Pfizer’s Abrysvo is under ACIP review for direct use in adults 60+.
• Pediatric Vaccines: Multiple candidates are in late-stage trials for infants and toddlers.
• Combination Vaccines: Research into co-administering RSV and flu vaccines is underway.
• Longer-Lasting Immunity: Next-gen candidates aim for protection spanning two RSV seasons.

Practical Tips for the Season

• Keep up with annual flu and COVID-19 vaccinations—co-circulation with RSV can increase hospitalizations.
• Practice good respiratory hygiene: cover coughs, wash hands and avoid crowded indoor spaces if you’re at high risk.
• Monitor local RSV activity through health department alerts or news sources.
• If you experience severe cough, wheezing or difficulty breathing, consider a free, online symptom check, using the doctor approved Ubie Symptom Checker.

Taking Action: Next Steps

1. Check your eligibility for RSV vaccination.
2. Speak with your doctor or pharmacist about scheduling a dose.
3. Plan for any mild side effects: rest, hydration and over-the-counter pain relievers as needed.
4. Monitor symptoms of respiratory illness—early intervention can prevent complications.

Important: Always speak to a doctor about any life-threatening or serious health concerns. Your provider can help you make informed choices about RSV vaccination and overall respiratory health.

Stay informed on the latest rsv vaccine news to protect yourself and loved ones this season.